SCHEMBL31015945

SCHEMBL31015945

O=C(O)c1sc2cc(Cl)ccc2c1-c1ccc(Cl)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 4/20 0.56
▸ BCKDK O14874 2/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.56
▸ KMO O15229 2/20 0.43
▸ BCL2L1 Q07817 3/20 0.41
▸ ESR1 P03372 5/20 0.41
▸ BCL2 P10415 2/20 0.40
▸ BAD Q92934 2/20 0.40
▸ ERCC5 P28715 1/20 0.39
▸ FEN1 P39748 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ RPA1 P27694 3/20 0.38
▸ ALDH1A1 P00352 1/20 0.36
▸ TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25237120 1.00 MCL1 (0.56) MCL1BCKDKRXFP1KMOBCL2L1
SCHEMBL25253110 0.90 BCKDK (0.60) MCL1BCKDKRXFP1KMOBCL2L1
SCHEMBL31015933 0.83 MAPT (0.43) MCL1BCKDKRXFP1NPC1RAB9A
SCHEMBL25209640 0.83 MAPT (0.43) MCL1BCKDKRXFP1NPC1RAB9A
SCHEMBL25575334 0.82 MCL1 (0.56) MCL1BCKDKRXFP1KMOBCL2L1
Ammonia Solution, Strong SCHEMBL25243752 0.81 MCL1 (0.55) MCL1BCKDKRXFP1KMOBCL2L1
SCHEMBL25202699 0.81 MCL1 (0.65) MCL1BCKDKRXFP1BCL2L1BCL2
SCHEMBL25217793 0.81 MCL1 (0.57) MCL1BCKDKRXFP1KMOBCL2L1
SCHEMBL25206026 0.80 MCL1 (0.60) MCL1BCKDKRXFP1BCL2L1BCL2
SCHEMBL25242010 0.79 MCL1 (0.58) MCL1BCKDKRXFP1KMOBCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118451066-A 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure 辉瑞大药厂 2024-08-06 — — CN disclosed
Send feedback